Pharvaris (NASDAQ:PHVS) President Sells 15,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $40.68, for a total value of $610,200.00. Following the completion of the sale, the president owned 65,179 shares of the company’s stock, valued at $2,651,481.72. The trade was a 18.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Peng Lu also recently made the following trade(s):

• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Stock Performance

NASDAQ PHVS traded up $0.03 on Wednesday, reaching $37.87. 472,007 shares of the stock traded hands, compared to its average volume of 375,401. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -12.42 and a beta of -2.33. The company has a fifty day moving average price of $34.86 and a 200-day moving average price of $31.20.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, research analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PHVS. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday. Wedbush set a $50.00 price target on Pharvaris and gave the stock an “outperform” rating in a research report on Wednesday. Citizens Jmp upped their price objective on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Royal Bank Of Canada raised their price objective on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Leerink Partners lifted their target price on Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.21.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Positive Phase 3 results support the stock: Pharvaris reported that the CHAPTER-3 pivotal study of deucrictibant XR met its primary endpoint and all secondary efficacy endpoints with statistically significant and clinically meaningful results. The oral therapy reduced HAE attacks in the prophylaxis setting, and the results are expected to support marketing-authorization applications beginning in the first half of 2027. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Analysts raised their valuation expectations: Royal Bank of Canada lifted its price target to $62 from $52 and maintained an “outperform” rating. Citizens JMP raised its target to $79 from $75 and retained a “market outperform” rating. These targets imply substantial upside and reflect increased confidence in deucrictibant XR’s clinical and commercial potential. RBC Raises Price Target on Pharvaris
• Positive Sentiment: Broad analyst support continues: HC Wainwright reaffirmed its “buy” rating with a $60 target, while Wedbush maintained “outperform” with a $42 target. The upgrades and reiterations indicate that the clinical win is being incorporated into forecasts and valuation models.
• Neutral Sentiment: Key risks remain: RBC continued to classify Pharvaris as a speculative investment. The company remains loss-making, and the drug still faces regulatory review, manufacturing, launch-execution and competitive risks before it can generate commercial revenue.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PHVS. Quantbot Technologies LP purchased a new stake in Pharvaris in the second quarter valued at about $41,000. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Barclays PLC purchased a new stake in shares of Pharvaris during the fourth quarter worth about $77,000. CoreCap Advisors LLC acquired a new position in shares of Pharvaris during the second quarter valued at about $93,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Pharvaris during the fourth quarter valued at about $139,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.